PMID: 3758140Jan 1, 1986Paper

Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication

European Journal of Clinical Pharmacology
W SchaumannA Smolarz

Abstract

17 patients with severe digoxin intoxication were successfully treated with 320 to 480 mg Fab fragments of digoxin-specific IgG from sheep. The infusion period ranged between 0.5 and 7 h. Serum and urine concentrations of digoxin bound to Fab fragments, and in 11 cases unbound Fab fragments in serum, were determined during and after the infusion. The renal clearance of bound digoxin and therefore of the antibody was 13.6 ml/min. The median extrarenal clearance of the Fab fragments was 10.9 ml/min. The half-life of the serum concentrations starting at 12 h was 14.3 h, and the value was increased to 25.4 h when regression began at 24 h; the corresponding apparent distribution volumes were 25.9 and 541. These figures exceed the volume of the extracellular space and suggest intracellular penetration of the Fab fragments. The dosage of the antibody should be sufficiently high to bind digoxin in the most severe cases of poisoning. The maximum serum concentrations of bound antibody were 30 mg/l after 3 h and 20 mg/l after 5 h. A loading dose of 160 mg followed by an infusion of 0.5 mg/min was sufficient to absorb digoxin re-diffusing into the serum during the first 8 h. In some cases free digoxin reappeared in the serum 8-12 h after b...Continue Reading

References

Oct 1, 1978·American Heart Journal·T HessW Riesen
Sep 7, 1979·Deutsche medizinische Wochenschrift·T HessW Riesen
Apr 8, 1976·The New England Journal of Medicine·T W SmithV P Butler
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
May 1, 1985·Journal of the American College of Cardiology·T L WengerT W Smith
Jan 1, 1980·Journal of Steroid Biochemistry·W W GrodyB W O'Malley
Sep 23, 1983·Deutsche medizinische Wochenschrift·G WahlM Schwartau

❮ Previous
Next ❯

Citations

Jan 4, 1989·Klinische Wochenschrift·E ErdmannW Schaumann
Feb 12, 2008·European Journal of Clinical Pharmacology·D N Bateman
May 24, 2012·Cardiovascular Toxicology·Saurabh RajpalPratap Reddy
Jan 1, 1996·Toxicon : Official Journal of the International Society on Toxinology·L SjostromD C Smith
Dec 1, 1995·Toxicology Letters·P R Pentel, D E Keyler
Jul 5, 1992·The New England Journal of Medicine·A D WoolfF H Lovejoy
Mar 9, 1995·The New England Journal of Medicine·F J BaudJ M Scherrmann
Oct 1, 2008·Critical Care Medicine·Frédéric LapostolleFrédéric J Baud
Nov 1, 1991·The Journal of Pharmacy and Pharmacology·M P Timsina, D S Hewick
Oct 1, 1992·The Journal of Pharmacy and Pharmacology·M P Timsina, D S Hewick
Dec 1, 1992·The Journal of Pharmacy and Pharmacology·A E SabouraudJ M Scherrmann
Oct 1, 1994·The Journal of Pharmacy and Pharmacology·R J MoranD S Hewick
Jul 9, 2003·Clinical Pharmacokinetics·José María GutiérrezBruno Lomonte
May 3, 2005·Toxicological Reviews·D Nicholas Bateman
Aug 5, 2014·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·B S H Chan, N A Buckley
Jan 1, 1989·Journal of Toxicology. Clinical Toxicology·J M ScherrmannJ M Bourre
Jan 11, 1992·Journal of Toxicology. Clinical Toxicology·W BannerW M Gooch
Jan 1, 1993·Journal of Toxicology. Clinical Toxicology·P TabouletC Bismuth
Apr 11, 2015·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Philip W PeakeZoltan H Endre
Jun 30, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M ZdunekM H Mokrzycki
Jan 17, 2012·British Journal of Clinical Pharmacology·David CzockHanna M Seidling
Sep 1, 1989·British Journal of Clinical Pharmacology·A J SinclairM Lemon
Nov 1, 1989·The Journal of Pharmacy and Pharmacology·M P TimsinaD S Hewick
Dec 1, 1993·Annals of Emergency Medicine·S A RichR J Locke
Jul 7, 1998·Toxicology and Applied Pharmacology·M Bazin-RedureauJ M Scherrmann
May 18, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Naoki AikawaTatsuya Maruyama
Jul 17, 2012·Journal of Immunological Methods·S L MalcolmS Shaw
Nov 18, 1997·Human & Experimental Toxicology·C BismuthJ M Scherrmann
Jan 18, 2018·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Michael EddlestonJean-Claude Alvarez
Oct 12, 2018·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Lucy M BrackenNicholas A Buckley
Dec 12, 1987·British Medical Journal·M LemonG A Georgiou
Nov 24, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Robert J Flanagan, Alison L Jones
Oct 31, 2009·American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses·Florian EyerThomas Zilker
Apr 23, 2016·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists
Dec 1, 1991·DICP : the Annals of Pharmacotherapy·N M AllenJ W Findlay
Jan 15, 1986·Klinische Wochenschrift·W Forth
Jul 28, 2019·Medicine·Mingjie FuAnwei Lu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.